Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review

Yan Yang¹, Zhengtao Chen¹, Xiaoyan Zhao¹, Hongyan Xie¹, Lian Du², Hong Gao¹* and Chunguang Xie¹*
¹Hospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, China, ²School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China

Obesity–insulin resistance–β-cells apoptosis is an important trilogy of the pathogenesis of type 2 diabetes. With the global pandemic of obesity and diabetes, continuous research and development of new drugs focuses on the prevention of the pathological progress of these diseases. According to a recent study, the natural product kaempferol has excellent antidiabetic effects. Therefore, this review comprehensively summarized the frontier studies and pharmacological mechanisms of kaempferol in the treatment of diabetes. The successful research and development of kaempferol may yield a significant leap in the treatment of diabetes and its complications.

KEYWORDS
kaempferol, diabetes, diabetes complications, obesity, mechanism

Introduction

Diabetes is a serious global public health concern. Approximately 451 million people were diagnosed with diabetes in 2017, and 693 million people are predicted to be diagnosed with diabetes by 2045 (1). Moreover, 374 million people have impaired glucose tolerance (1). The prevalence of diabetes varies slightly across countries and regions. It affects nearly 25.8 million people in the United States, accounting for 8.3% of the total population (2). The morbidity rate of diabetes is 11.2% among Chinese adults (3). The incidence rate of diabetes in obese and overweight individuals has increased significantly (4). The development of new antidiabetic drugs, including sodium-glucose cotransporter 2 inhibitors, has improved the survival rate of patients with diabetes. Unfortunately, the morbidity associated with diabetes continues to increase. Therefore, the continuous development of new antidiabetic drugs is inevitable (5–8).

The prevalence of diabetes is associated with an increase in obesity (9). According to the World Health Organization, more than 1.9 billion adults worldwide are
overweight, and more than 600 million people are obese (10). Excess adipose tissues in obesity release nonesterified fatty acids (NEFAs), glycerol, adipokines, and pro-inflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin [IL]-6, IL-1β), leading to insulin resistance (IR) and type 2 diabetes mellitus (T2DM) (11). Lipid metabolism disorders, chronic inflammation and IR caused by obesity are the core pathogeneses of T2DM. Chronic exposure to NEFAs is associated with impaired glucose-stimulated insulin secretion and decreased insulin biosynthesis (12). Increased NEFA and glucose levels can occur simultaneously, and when combined, these two are significantly detrimental and lead to “glycolipid toxicity” (13). IR acts as a bridge between obesity and T2DM. Some insulin-resistant individuals maintain normal blood glucose levels. This is because islet β cells overcome the decrease in insulin efficiency by increasing insulin release (14, 15). β cells play an important role in the pathogenesis of type 2 diabetes. Expectedly, β-cell dysfunction exists in insulin-resistant individuals with normal blood glucose levels (16). In patients with type 2 diabetes, the number of β cells decreases by approximately 50%, and only 25% or less of β cells can function (17). Therefore, “obesity–IR–β-cell apoptosis” results in diabetes and its complications.

The natural product kaempferol, extracted from plants, has become the focus of studies. In recent years, natural products have accounted for 30% of global clinical drugs, and more than 65% of the global population uses natural products to treat diseases (18, 19). The development of natural products for the treatment of diabetes has attracted considerable attention (20, 21). The use of natural plants such as Ginkgo biloba, galangal, and Pueraria, has a long history, especially in Asia.

Kaempferol (3,5,7-trihydroxy-2-[4-hydroxyphenyl]-4H-1-benzopyran-4-one) is a natural flavonoids compound with a low molecular weight (286.2 g/mol) (22). It can be found in traditional medicines, such as Sophora japonica, ginkgo, and galangal, and in foods, such as beans, cauliflower, cabbages, gooseberry, grapes, cabbages, strawberries, tea, and tomatoes (22). Kaempferol has anti-inflammatory (23), anti-oxidative stress (24), antitumor (25), anti-atherosclerotic (26), hypoglycemic (27), and hypolipidemic (28) effects.

In this article, we discussed the antidiabetic mechanisms of Kaempferol Figure 1 from three perspectives. Kaempferol regulates lipid metabolism and improves IR to reduce lipotoxicity. Second, kaempferol improves insulin signaling and restores the balance between glucose utilization and production, thereby improving glucose toxicity. Finally, kaempferol restores the imbalance in autophagy-apoptosis to protect β cells. Therefore, the antidiabetic mechanisms of kaempferol is to comprehensively prevent the progression of “obesity–IR–β-cell apoptosis–diabetes–diabetic complications” (Table 1).

**Anti-lipotoxicity effect of kaempferol**

With the lipid accumulation in adipose tissues during obesity, fat macrophages release inflammatory cytokines, such as TNF-α and IL-6. In insulin-sensitive organs, these cytokines stimulate c-Jun amino terminal kinase (JNK) and IκB kinase-β/nuclear factor-κB (NF-κB) pathways, blocking insulin signaling, IR results in T2DM (52). In IR, the function of insulin in
## TABLE 1 Mechanism of kaempferol anti-diabetes.

| Experimental Object | Kaempferol Dosage | Modes of Antidiabetic Action | Related Signaling Pathways or Targets | References |
|---------------------|-------------------|------------------------------|---------------------------------------|------------|
| JT3-L1 cells; zebrafish | JT3-L1 cells: 7.5/15/30 μM zebrafish: 5/10/20 μM | (a) fatty acid synthesis; (b) triglyceride synthesis; | PPARγ, C/EBPα and ap2 | 29 |
| | | | | |
| JT3-L1 cells | 5 μM, 40 μM | (a) Lipid Accumulation; (b) Fatty Acid Oxidation; | PPARγ, LXRA, SREBP-1c and C / EBPA | 30 |
| Male Wistar rats | 75, 150 or 300 mg / kg | (a) fatty acid oxidation; | SREBP-1a ↓ | 31 |
| Human mesenchymal stem cells (hMSCs) | 1 μM, 10 μM and 25 μM | (a) adipogenesis; (b) lipolysis; (c) insulin resistance; | C/EBPβ And SREBP1c; ATGL ↑ | 32 |
| C57BL / 6 mice | 200 mg / kg | (a) blood glucose; (b) lipolysis; (c) Regulating intestinal flora | intestinal flora ↑ | 33 |
| SHEPG2 cells (liver) | 10 μM, 20 μM | (a) hepatic triglyceride accumulation; | Akt and SREBP-1c; Akt-MTORC1 dependent autophagy pathway. | 34 |
| THP-1 cells | 2.5 μg / ml; 5 μg / ml; 10 μg / ml | (a) Macrophages lipid accumulation ↓; (b) Prevention of atherosclerosis; | CD 36↓ | 35 |
| | | | ABCA1, ABCG1↑ | |
| In vitro: HeLa cells. JT3-L1 cells. In vivo: Rats. | 20 μg / M, 10 mg / kg | (a) Lipid autophagy; (b) lipolysis degradation; (c) lysosomal Ca2+ efflux; (d) TFEB translocation; | ATG5-ATG12 ↑ | 36 |
| | | | TUFM ↑ | |
| JT3-L1 cells | 60 μM | (a) lipolysis; (b) lipid accumulation; (c) fat differentiation; | CEBP-α↓ | 28 |
| | | | PNPLA2 and LIPE↑ | |
| Male TSOD mice and TSNO mice | 5 mg / kg; 15 mg / kg | (a) lipid synthesis; (b) fatty acid oxidation; (c) liver cholesterol transport; | LXR, SREBP-1c | 37 |
| | | | PPAR α↑ | |
| | | | ApoA1↑ | |
| HepG2 cells | 5 μM, 10 μM, 20 μM | (a) lipid accumulation ↓; (b) oxidative stress ↓; | SREBP1, FASSCD-1 | 38 |
| | | | PPARγ, C/EBPβ↑ | |
| JT3-L1 cells | 50 μmol / L | (a) the early stage of adipogenesis; | MCE↑ | 34 |
| | | | apoptosis↑ | |
| MaleC57BL/ 6 J mice | 10 mg / kg | (a) lipid metabolism; (b) glucose metabolism; | PPARy/LXRα/ABCA1↑ | 39 |
| | | | PPAR/PI3K/akt↑ | |
| In vivo: db/db mice; In vitro: MIN6 pancreas β Cells | 50 μM, 100 μM | (a) lipid metabolism; (b) glucose metabolism; (c) β-cell proliferation; | SREBP-1↑ | 40 |
| | | | IRS/PI3K/akt↑ | |
| | | | IRS2/FOXO1↑ | |
| ApoE C57BL / 6j male mice | 150 mg / kg | (a) plasma glucose ↓; (b) insulin sensitivity↑; (c) high-density lipoprotein cholesterol levels↓; | LXR-β↑ | 41 |
| | | | Akt + , SREBP-1↓ | |
| Male Wistar rats. | 50, 100, and 200 mg / kg | (a) blood glucose↓; (b) antioxidant↓; | Lipid peroxidation↓ | 42 |
| Male Wistar rats. | 100 mg / kg | (a) membrane-bound ATPases↑; (b) antioxidant↑; | – | 43, 44 |
| Yeast glucosidase | Kaempferol solution (6.82 * 10−6 mol / L) | (a) Blood glucose↓; | α-glucosidase | 45 |
| Male C57BL/6j mice | 50 mg / kg | (a) hepatic gluconeogenesis↓; (b) glycogen synthesis↑; (c) Blood glucose↓; | PC and G6P ↓ | 27, 46 |

(Continued)
TABLE 1 Continued

| Experimental Object | Kaempferol Dosage | Modes of Antidiabetic Action | Related Signaling Pathways or Targets | References |
|---------------------|------------------|-----------------------------|--------------------------------------|------------|
| RIN-5F cells        | 1µM, 10µM and 50µM | (a) Lipotoxicity ↑; (b) pancreatic β-cells apoptosis ↓; | AMPK/mTOR↑ | 47 |
| IN-5F cells         | 10µM             | (a) Lipoligphy ↑; (b) ER stress ↓; (c) β-cell mass and function | AMPK/mTOR↑ | 48 |
| HeLa cells          | 1µM              | (a) Anti diabetes and diabetic complications | Ca2+ uniporter↑ | 49 |
| INS-1E β Cells      | 0.1µM, 1µM and 10µM | (a) pancreatic β-cells apoptosis ↓; (b) β-cells secrete insulin ↑; | PDX-1/cAMP/PKA/CREB↑ and MCU↑ | 21, 50 |
| INS-1E β Cells, Human islet (CMRL-1066) cells | 0.01µM, 0.1µM, 1 µM and 10µM | (a) apoptosis ↓; (b) pancreatic β-cells↑ | caspase-3↓ | Akt and Bcl-2↑ | 51 |

*↑* refers to upregulation, and *↓* refers to downregulation.

inhibiting lipolysis is impaired, and free fatty acids (FFA) levels increase. Subsequently, these fatty acids are deposited in insulin-sensitive organs and tissues, such as the liver, skeletal muscle, and pancreas. Lipid metabolism disorders are a characteristicis of T2DM.

According to a previous study, an increase in circulating FFA levels occurred earlier than glucose intolerance (53). FFAs are transported to the liver and metabolized into acetyl coenzyme A (CoA), which enhances the activity of pyruvate carboxylase (PC) and provides a substrate for gluconeogenesis (54). Glycerol released from lipolysis is also a direct substrate for hepatic gluconeogenesis (55). One of the mechanisms by which metformin inhibits diabetes is the inhibition of gluconeogenesis using glycerol as a substrate. The “glucose fatty acid cycle” is usually used to describe glucose metabolic damage induced by FFAs (56). Theoretically, hyperglycemia can be corrected by removing the excessive accumulation of ectopic lipids (57, 58).

Anti-adipogenic effect of kaempferol

Chronic overnutrition and obesity are usually associated with IR and hepatic steatosis (fatty liver) (59). Under nutrient-rich conditions, the expression and transcription of fatty acid synthesis genes are upregulated, leading to increased fatty acid synthesis. Sterol regulatory element-binding proteins (SREBPs) are adipogenic transcription factors that contain two subtypes SREBP1 and SREBP2. SREBP1c is the main subtype expressed in most tissues, whereas SREBP1a is highly expressed only in some tissues and cells (heart, macrophages) (60). SREBP2 regulates cholesterol metabolism (61). SREBP2 activity is controlled by downstream products of the cholesterol biosynthesis pathway with a highly regulated negative feedback mechanism (62). When SREBP2 is transferred to the nucleus, it activates the expression of cholesterol-related genes, such as 3-hydroxy-3-methylglutaryl-CoA reductase and low-density lipoprotein receptor (LDLR) (63). Nevertheless, the mechanism by which SREBP2 regulates cholesterol homeostasis is complex, and there may be different regulatory mechanisms in different organs. In the liver, berberine inhibits hepatic cholesterol deposition by downregulating the silent mating type information regulation 2 homolog (SIRT1)-forkhead box protein O1 (FOXO1)-sSREBP2 pathway (64). In the aorta, metformin inhibits SREBP2-LDLR-mediated aortic cholesterol uptake by activating activated protein kinase (AMPK) (65). However, there are no direct experimental data to confirm that SREBP2 is a mechanism by which kaempferol regulates lipid metabolism disorders. Notably, this aspect deserves further study.

SREBP1c (Figure 2) primarily controls the expression of adipogenic genes and regulates fatty acids. During IR, chronic hyperinsulinemia overactivates the liver protein kinase B (Akt)/mammalian target of rapamycin complex 1 (mTORC1)/SREBP1c pathway, inducing excess adipogenesis (66). This is one of the causes of lipid metabolism disorders in patients with diabetes. In detail, Akt (threonine protein kinase) phosphorylates and inhibits insulin-induced gene (INSIG2), which transports SREBP-SREBP cleavage-activating protein complex to the Golgi apparatus for proteolytic degradation (67). Akt phosphorylates and inhibits glycogen synthase kinase 3 (GSK3) β/F-box and WD repeat domain containing 7-mediated ubiquitin precursor system, thereby reducing SREBP degradation (68). mTORC1 promotes SREBP1 activation and lipid synthesis by interacting with ribosomal protein S6 kinase (S6K) (69). Moreover, mTORC1 inhibits tuberous sclerosis complex (TSC) (an upstream inhibitor of mTORC1) through Akt-mediated phosphorylation, whereas phosphorylated mTORC1 secretes the nuclear phosphatase lipin-1, thereby activating nuclear SREBP1c (70). Once SREBP1c is activated, insulin signaling is blocked (71).
Kaempferol downregulates SREBPs and upregulates liver peroxisome proliferator-activated receptor α (PPARα), promoting the expression of propyl CoA oxidase and cytochrome P450 isomer 4A1 reducing the accumulation of visceral fat, and improving hyperlipidemia in high-fat diet-fed obese rats (31). Kaempferol upregulates liver X receptor (LXR), which regulates lipid transport (37, 41). Therefore, kaempferol exhibits a strong lipid-regulating effect in different cell types. In adipocytes, differentiated from human mesenchymal stem cells, kaempferol downregulates the CCAAT enhancer binding protein (C/EBP) β and SREBP1c, and upregulates the expression of adipose triglyceride (TAG) lipase (ATGL) to inhibit the accumulation of TAGs (32). In 3T3-L1 cells, kaempferol inhibits TAG synthase (such as LPAAT, lipon-1[LPIN1] and diacylglycerol [DAG] acyltransferase 1), fatty acid synthase (FASN), and SREBP1c related fatty acid synthesis to inhibit lipid accumulation (30). Kaempferol inhibits mitotic clonal expansion and induces apoptosis in the early stages of adipogenesis (34). In HepG2 cells, kaempferol inhibits Akt activity and SREBP1 through a variety of mechanisms, increasing the expression of INSIG-2a, reducing SREBP1 phosphorylation, and increasing GSK-3 phosphorylation (72).

Kaempferol regulates lipolysis and transport

Under the condition of excess energy, fuels are stored in adipocytes as TAGs. The fat storage capacity of adipocytes prevents lipotoxic damage (lipid-induced dysfunction and programmed cell death) in tissues and organs (especially the skeletal muscle, liver, and pancreas) (73). Lipolysis is defined as the decomposition of TAGs into glycerol and non-acylated fatty acids (NEFAs) with the release of energy (74). The main hormones that regulate lipolysis are catecholamines and insulin. Catecholamines promote lipolysis, whereas insulin inhibits lipolysis. Insulin regulates the uptake of glucose and fatty acids in adipocytes and triggers the translocation of fatty acid transport (75). Insulin strongly inhibits basal lipolysis and catecholamine-induced lipolysis by activating phosphodiesterase-3b (PDE-3B) through PKB/Akt-dependent phosphorylation (76). PDE-3B reduces cyclic adenosine monophosphate (cAMP) levels, downregulates protein kinase A (PKA) activation, and reduces PKA-stimulated hormone-sensitive lipase (HSL) phosphorylation by catalyzing cAMP decomposition into inactive forms (76). Insulin also activates the regulatory subunit of protein
phosphatase-1 by phosphorylation, causing rapid HSL dephosphorylation and inactivation (77).

In addition, inflammatory cytokines such as TNF-α, IL-6, and IL-1β, secreted by adipocytes and adipocytes promote lipolysis. The mechanisms by which TNF-α promotes lipolysis are as follows. First, insulin signaling is inhibited by tyrosine phosphorylation of insulin receptor substrate 1. Perilipin is a protective protein around lipid droplets that prevents lipid droplets from being decomposed by HSL (78). However, TNF receptor 1 reduces perilipin through mitogen-activated protein kinase (MAPK) (p44/42, JNK) (79). IL-1β is another significant pro-inflammatory cytokine that is mainly produced by macrophages. In human adipocytes, IL-1β inhibits insulin signal transduction and glucose transporter type 4 (GLUT4) at doses as low as 2 ng/ml (80). During IR, the inhibition of perilipin allows lipase to enter lipid droplets. After lipase activation, TAGs are decomposed in three steps. Initially, TAGs are hydrolyzed by ATGL to produce fatty acids and DAG (81). HSL catalyzes the hydrolysis of DAG to monoacylglycerol (MAG) and fatty acids (82). Finally, MAG lipase hydrolyzes MAG to fatty acids and glycerol (83).

It differs from hyperlipidemia caused by excessive lipolysis during inflammation and IR. The ultimate goal of kaempferol in the regulation of lipid metabolism is to reduce ectopic lipid deposition and maintain lipid homeostasis. Kaempferol at 60 µM stimulates 62% inhibition of adipogenesis in preadipocytes and results in a 39% reduction in intracellular lipid accumulation in mature adipocytes (28). The PPARβ/δ signaling cascade regulates the expression of PPARγ and C/EBP family (84, 85). PPARγ and C/EBP are pivotal transcriptional regulators of lipid homeostasis, regulating the expression of FASN, ATGL, and HSL (29, 86). Kaempferol downregulates PPARγ and C/EBP-β to activate ATGL and directly promotes lipolysis in a concentration-dependent manner (29). Patatin-like phospholipase domain containing 2 (Pnpla2) and Lipe also encode ATGL and HSL, respectively (87). In 3T3-L1 cells, kaempferol upregulates the mRNA expression of Pnpla2 and Lipe, indirectly increasing the expressions of ATGL and HSL (28). LPIN1, a co-regulator of DNA-bound transcription factors, is highly expressed in adipocytes and functions as a phosphatidic acid (PA) phosphatase enzyme that dephosphorylates PA to DAG (88). LPIN1, PPARγ coactivator α, and PPARα synergistically regulate fatty acid oxidation gene expression (89). Kaempferol downregulates the protein level of LPIN1 in a dose-dependent manner (29), which seems to be related to the downregulation of PPARγ. LXR maintains cholesterol homeostasis by regulating cholesterol efflux, transportation, and absorption (90). The use of LXR agonists (fibrates) activates SREBP1c, eventually leading to fatty liver and hypertriglyceridemia (59). Kaempferol activates LXR, especially the β subtype, which lowers cholesterol and glucose levels in apolipoprotein E-deficient mice (41). However, the expression of LXR β is not highly in the liver; therefore, the selective activation of LXR β by kaempferol does not cause an increase in SREBP1c. In macrophages, lipids are absorbed by scavenger receptor A and cluster of differentiation 36 (CD36) (91). Cholesterol is transported to the outside of the macrophages by reverse cholesterol transporters, including scavenger class B type 1 (SR-B1), ATP-binding cassette transporter A1 (ABCA1), and ATP binding cassette transporter G1 (ABCG1) (92, 93). Kaempferol downregulates CD36 and upregulates SR-BI, ABCA1, and ABCG1 (35). The phagocytosis of lipid-forming foam cells by macrophages is an early marker of atherosclerosis. Therefore, kaempferol is likely to have anti-atherosclerotic effects. Similar to other phenolic substances different kinds of kaempferol have strong anti-inflammatory effects. Kaempferol glycosides inhibit the expression of the transcription factor PPARγ and decrease TNF-α levels (94). In contrast, kaempferol inhibits the pro-inflammatory signals of TNF-α, IL-6, IL-1β, and NF-κB (95–97). Evidently, anti-inflammation is also a good measure to regulate metabolic disorders and diabetes.

Kaempferol improves glucose metabolism

Insulin resistance and hyperglycemia

The discovery and administration of insulin are milestones in the treatment of diabetes, which transforms diabetes from a life-threatening disease to a controllable disease (98). Insulin binds to the insulin receptor on the outer surface of the cell, causing tyrosine phosphorylation of insulin receptor substrate, and then binds to inosine phosphate 3-kinase to form phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 activates Akt, 3-phosphoinositol dependent protein kinase 1, which then activates P70 ribosomal S6 kinase (S6K) and protein kinase C (99). Akt-dependent phosphorylation plays an important role in the physiological effects of insulin. First, Akt-induced phosphorylation causes GSK3α/β inactivation, which leads to dephosphorylation and activation of glycogen synthase (100). Second, Akt phosphorylates the TBC1 domain family member 1/AKT substrate of 160 kDa (TBC1D4/AS160) to regulate the transport of intracellular GLUT4 vesicles to the cell membrane to increase glucose uptake (101, 102). Third, Akt phosphorylation of TSC2 leads to mTORC1 activation, which stimulates lipid and protein synthesis and inhibits autophagy (103, 104). Fourth, Akt phosphorylates and inhibits the translational FOXO transcription to the nucleus, thereby inhibiting liver glucose-producing gene and muscle autophagy gene expressions and lipolysis (105, 106). Interestingly, in
contrast to insulin inhibition of FOXO transcription, insulin induces Akt and mTORC1 activation by inhibiting GSK3\(\alpha/\beta\), thus inhibiting forkhead box class K (FOXK) phosphorylation and causing FOXK nuclear localization and transcription \((107)\). FOXK regulates the expression of genes involved in cell cycle, apoptosis, and lipid metabolism and even stimulates glycolysis \((108)\).

Insulin plays a role in regulating metabolism in different insulin sensitive-tissues through subsequent recognition signal transduction with insulin receptor substrates and tyrosine kinase activity \((109)\). In the skeletal muscles, insulin promotes glucose transport and utilization, stimulates glycogen synthesis, and inhibits protein decomposition. In adipose tissues, insulin promotes glucose transport and lipogenesis, and inhibits lipolysis. In the liver, insulin inhibits gluconeogenesis and fatty acid oxidation and stimulates glycogen synthesis and lipogenesis \((\text{de novo} \text{ lipogenesis})\) \((110)\). In IR, hepatic gluconeogenesis and hepatic glucose production are increased. However, glycogen synthesis and glucose uptake are blocked, resulting in an increased hepatic glucose output and elevated blood glucose levels.

**Multi-target hypoglycemic effects of kaempferol**

Relative or absolute deficiency of insulin secretion and insulin action is the basic pathogenesis of diabetes. Kaempferol can interfere with the above process through many ways \((\text{Figure 3})\). Kaempferol promotes insulin secretion, which is similar to insulin secretagogue. A study using glibenclamide, an insulin secretagogue, as the control drug, found that kaempferol increased the plasma insulin levels and reduced blood glucose levels in streptozotocin-induced diabetic rats \((43)\). Mitochondrial Ca\(^{2+}\) plays an important role in insulin release and glucose metabolism \((111)\). Mitochondrial calcium monopporter (MCU) is the main pathway of Ca\(^{2+}\) uptake in the mitochondria \((112)\). Kaempferol directly activates MCU in a concentration-dependent manner. only 1\(\mu\)M can nearly double the uptake of mitochondrial Ca\(^{2+}\) and then activate the pancreatic \(\beta\)-cell metabolism/secretion coupling \((49, 50)\). In a C57BL/6 mouse model of diabetic nephropathy (DN), kaempferol increased glucagon-like peptide 1 (GLP-1) and insulin levels with an increase in cAMP, Ca\(^{2+}\) and glutathione (GSH) levels \((113)\). Kaempferol also improves insulin-
dependent glucose uptake in 3T3-L1 adipocytes and pig myotubes (114, 115).

An imbalance in glucose production and utilization causes glucose metabolism disorders. Hepatic IR is an important cause of fasting hyperglycemia. Under the condition of hepatic IR, glucose metabolism-regulating enzymes levels, such as glucose-6-phosphatase, PC, glucokinase (GCK) and phosphoenolpyruvate carboxykinase (PEPCK), are abnormal. The activation and inactivation of GCK are closely related to blood glucose levels. Therefore, GCK activator is a potential target for the treatment of diabetes (116). Kaempferol reduces blood glucose levels by increasing GCK levels and promoting glycogen synthesis (46). In mice, oral administration of kaempferol (50mg/kg/day) significantly improves hyperglycemia by restoring the activity of hexokinase, while inhibiting the activity of PC and gluconeogenesis, thus reducing the morbidity rate of diabetes from 100% to 77.8% (27). When insulin signaling is activated, Akt phosphorylates and inhibits FOXO1 transcription, ultimately inhibiting PEPCK and G6P expressions (117, 118). The mechanism by which kaempferol inhibits hepatic gluconeogenesis is also includes a direct increase in Akt activity and PC inhibition (46). Kaempferol inhibits the hepatic inhibitor IκB kinase/NF-κB pathway as its anti-inflammatory effect and restores Akt activity (119).

Adenosine 5′-monophosphate (AMP)-AMPK is one of an important energy sensor and the main regulator that maintains systemic metabolic homeostasis (120). IR is accompanied by a sustained decrease in AMPK activity, which increases insulin sensitivity (121, 122). AMPK inactivates acetyl CoA carboxylase (ACC) by phosphorylation, thus preventing malonyl-CoA synthesis, increasing mitochondrial fatty acid oxidation, and reducing fatty acids synthesis (123). AMPK activation is an important pharmacological target for diabetes treatment. Metformin and thiazolidinediones (TZDs) have been identified as AMPK activators (124, 125). Kaempferol increases the phosphorylation of AMPK and ACC in the adipose tissues, liver, and muscles (126, 127). Therefore, kaempferol is possibly the same as metformin and TZDs as a direct activator of AMPK.

α-Glucosidase hydrolyzes glucoside bonds to glucose, which plays an important role in carbohydrate metabolism, and is therefore an attractive therapeutic target for the treatment of diabetes, obesity, and metabolic syndrome (128). Kaempferol is a novel α-glucosidase inhibitor. Kaempferol blocks its catalysis to glucoside by inserting into the active site of α-glucosidase, occupying the catalytic center of the enzyme and inducing conformational changes (45). Therefore, foods rich in kaempferol can reduce carbohydrate absorption and reduce postprandial glucose levels. Change in the intestinal microbiota are important in the pathogenesis basis of obesity, type 2 diabetes, and metabolic syndrome (129).

Kaempferol reduces the relative abundance of thick-walled flora, increases the level of Bacteroides, reduces blood lipids and glucose levels, and improves IR in obese C57BL/6 mice (33).

**Kaempferol protects pancreatic β cells**

Most patients with diabetes experience β cells mass loss and apoptosis (17). Pro-inflammatory factors, such as IL-1β, interferon and TNF-α induce β-cell apoptosis. The caspase-dependent intrinsic apoptotic pathway is the initial effecter of inflammatory β cells apoptosis (130). TNF-α and IL-1β induce NF-κB activation (131). NF-κB then reactivates inducible nitric oxide synthase expression, which subsequently causes the release of nitric oxide (NO) (132). NO-dependent Ca2+ depletion in the endoplasmic reticulum (ER) leads to ER stress, C/EBP homologous protein (CHOP) induction, and finally β Cells apoptosis (133, 134). However, the proapoptotic and antiapoptotic effects of NF-κB activation are controversial among different cell types. The activation of NF-κB promotes apoptosis after exposure to IL-1β or TNF-α in β cells (131). The IL-1β/NF-κB pathway is considered the "common pathways" of β cells death in types 1 and 2 diabetes (135).

Autophagy is defined as an intracellular lysosomal degradation process of defective proteins, macromolecules, damaged organelles, and toxic aggregates and plays a crucial role in maintaining intracellular balance (136). Autophagy disorders are associated with IR, obesity, and T2DM (137, 138). Exposure of human islets β Cells to fatty acids and high glucose levels leads to apoptotic cell death by preventing autophagic flux (139). Overactivation of autophagy is related to an increase in lipolysis, resulting in ectopic lipid deposition and lipotoxic damage in β cells.

The mTOR/AMPK pathway and autophagy-related genes (ATGs) play a significant role in the regulation of autophagy (140). Microtubule-associated protein light chain 3-II (LC3-II) and p62 are markers of autophagy. Inhibition of the autophagy negative regulator mTOR improves IR and hepatic steatosis in T2DM rats (141). Kaempferol is an excellent autophagy enhancer (Figure 4). The activation of autophagy induced by kaempferol promotes intracellular lipid degradation, reduces ER stress, and protects β cells from lipotoxic damage (142). Kaempferol interacts with Tu translation elongating factor, mitochondrial (TUFM). TUFM enhances the interaction between ATG12–ATG5 complexes, thereby promoting the formation of autophagosomes and lysosomes. Transient receptor potential mucolipin 1 (TRPML-1) is a permeable cation selective channel that promotes intracellular calcium release (143). Mitochondrial reactive oxygen species (mtROS) regulates TRPL-1-mediated lysosomal Ca2+ release (143). As an autophagy enhancer, kaempferol induces mtROS to promote lysosomal Ca2+ efflux, transcription factor EB translocation, and autophagy induction (36). In this study, the authors believe that the enhanced autophagy of 3T3-L1 and HeLa cells induced by kaempferol is not related to AMPK-mTOR signaling (36). In contrast, in RIN-5F cells treated with palmitic acid, 10 μM
Kaempferol increased AMPK phosphorylation, decreased mTOR phosphorylation, reduced caspase-3 cleavage by approximately 2.5 times, and reduced the mortality rate of RIN-5F cells from 32% to 2% (47). In another study, 10 μM kaempferol treatment increased the colocalization of lipid droplets with autophagosomes and lysosomes in cells through AMPK-mTOR signaling and reduced ectopic lipid accumulation and ER stress (48). Kaempferol also plays an anticancer role by activating the IRE1/JNK/CHOP signaling pathway (144).

Diabetes is also closely associated with oxidative stress. Since oxidative stress was observed in experimental diabetes in the 1980s (145), the role of oxidative stress in the pathogenesis of diabetes and its complications has attracted extensive discussion in academia. In diabetes, persistent hyperglycemia eventually leads to excess production of reactive oxygen species (ROS) by increasing mitochondrial oxygen consumption, destroying mitochondrial function, or activating nicotinamide adenine dinucleotide phosphate oxidase (146). Excess ROS-induced β Cells dysfunction and IR are the main causes of diabetes and its complications. Consistent with other natural products, kaempferol has an excellent antioxidant effect. In diabetes, kaempferol prevents pancreatic β cells oxidative damage (40, 42, 51, 147). This may be related to kaempferol restoring the levels of nonenzymatic antioxidants (vitamins C and E, reduced GSH) and enzymatic (superoxide dismutase, catalase, GSH peroxidase, and GSH-S-transferase) antioxidants to reduce glucose and lipid peroxidation in β cells (43).

Kaempferol prevents myocardial hypertrophy by inhibiting the ASK1/MAPK signaling pathway, regulating oxidative stress, improving cardiac function, and reducing apoptosis (148). In male albino Wistar rats, the use of kaempferol reversed the increase in γ-glutamyl transferase and lipid peroxidation marker (thiobarbituric acid reactive substances and lipid hydroperoxides) levels (149). In rats with cerebral ischemia/reperfusion injury, 10–15 μmol/L kaempferol reduces nitrous oxidative stress after ischemia/reperfusion and inhibits apoptotic cell death and apoptotic biochemical markers (such as caspase-9 activity and poly [ADP-ribose] polymerase [PARP] degradation) for brain protection (150).

Diabetes-related hyperlipidemia and changes in membrane phospholipids and fatty acids inhibit membrane-bound enzyme activity (151). Membrane-bound ATPase contains Na⁺/K⁺-ATPase, Ca²⁺-ATPase, and Mg²⁺-ATPase, which are channels for cations to enter and leave cells. It plays an important role in maintaining cell physiological functions and is closely related to pathological changes. The use of kaempferol in diabetic rats significantly increases the activity of membrane-bound ATPases in the erythrocyte, liver, kidney, and heart tissues (44). This is another mechanism by which kaempferol protects β cells.

Kaempferol’s role in antidiabetic complications

Diabetic retinopathy

Diabetes is usually associated with one or more complications. Diabetic retinopathy is a common microvascular complication. In hyperglycemia-induced retinal ganglion cell (RGC) injury, 60 μmol/L of kaempferol reduces RGC cell damage and improves cell survival by increasing extracellular signal-regulated kinase phosphorylation and vascular inhibitor protein 1 expression (152). Retinal pigment epithelium (RPE) damage is associated with diabetic retinopathy progression. Oxidative stress caused by glucotoxicity and lipotoxicity is the main inducer of RPE injury. Kaempferol inhibits vascular endothelial growth factor mRNA...
expression and the bax/bcl-2/caspase-3 signaling pathways, thus protecting human RPE cells (ARPE-19) from hydrogen peroxide-induced injury and apoptosis (153). A prior large-scale study found that kaempferol at a dosage of 5–25 μm has antiangiogenesis effects (154). Interestingly, kaempferol inhibits estrogen-related receptors α, thus also inhibiting the angiogenesis of human retinal endothelial cells (155).

Diabetic nephropathy

DN is the most prevalent diabetes complications with the highest prevalence and accounts for 30–47% of all kidney diseases (156). Damage to glomerular mesangial cells (GMCs) is a key risk factor for early-stage DN. The interaction between advanced glycation end products (AGEs) and their receptors (RAGE) is an important mechanism of GMC damage. Kaempferol protects GMC to prevent DN. The mechanisms of kaempferol in DN include inducing antioxidative stress, inhibiting collagen IV and transforming growth factor-β1, improving mitochondrial membrane potential, and inhibiting the mitochondrial/cytochrome C-mediated apoptosis pathway (157). In hyperglycemia-induced podocyte apoptosis, kaempferol regulates M1/M2 polarization of glomerular macrophages and reduces TNF-α and IL-1β levels (3). Glomerular matrix fibrosis is another predisposing factor for DN progression. Kaempferol promotes the release of GLP-1 and insulin while inhibiting RhoA/Rho kinase and fibrosis (113). Chronic inflammation is also a key factor in DN progression. Kaempferol blocks Toll-like receptor 4, and NF-κB by downregulating TNF receptor-associated factor 6 to reduce the inflammatory response in DN (158).

Diabetic cardiomyopathy

Diabetic cardiomyopathy (DCM) is a major cardiovascular complication of diabetes that leads to heart failure and even death (159). Increased production of ROS, inflammation, cardiomyocyte apoptosis, and myocardial fibrosis are involved in the pathogenesis of DCM (160). Kaempferol upregulates SIRT1 (161), inhibits NF-κB nuclear translocation, and activates nuclear factor E2-related factor (162), thereby inhibiting diabetes-induced myocardial inflammation and oxidative stress. Kaempferol inhibits ASK1/MAPK signaling and regulates oxidative stress to prevent cardiac hypertrophy (148). In diabetes myocardial ischemia/reperfusion injury, kaempferol reduces the oxidative stress and inflammation induced by AGE-RAGE/MAPK to alleviate myocardial ischemia/reperfusion injury (163).

Moreover, kaempferol promotes wound healing in patients with and without diabetes by promoting wound reepithelialization (164).

In DN, kaempferol partially reverses pain sensitivity by regulating oxidative and nitrosative stresses and reducing AGES formation (165).

Conclusion and outlook

Obesity and diabetes are two chronic inflammatory diseases. NF-κB activation plays an important role in these diseases. This is inseparable from PARP1 (166, 167). PARP activation induced by lipotoxicity in the liver causes a decrease in NAD+, SIRT1, LXR, and AMPK levels and insulin receptor activation (168, 169). Inhibiting PARP1 prevents β-cell death (170, 171). Kaempferol activates AMPK and PPARα; suppresses C/EBP-α, SREBP1c, and PPARγ; and protects β Cells (38, 39). Therefore, kaempferol may serve as a natural PARP inhibitor.

Low plasma concentrations of kaempferol restrict its use. In fact, the flavonoid naturally absorbed by the human body is only 1–2 g per day, and the plasma concentration is in the range of micromolars (172). However, kaempferol at concentrations as low as 1 μM increases mitochondrial Ca2+ uptake by approximately 85% (49). A previous in vitro study found that kaempferol was not cytotoxic at a concentration of 60 or 75 μM (28, 47). Low bioavailability is another limiting factors for clinical studies on kaempferol (173, 174). The body has a defense mechanism that excludes foreign objects through cell membrane surface receptors (173). Interestingly, two methods that may improve the bioavailability of kaempferol. The first method is binding to another substance with higher affinity for the transporter protein, which transports substances with higher affinity to the outside of the cell, while those with lower affinity remain and continue to work. This method was validated for the binding of kaempferol and quercetin to the breast cancer drug resistance protein (ABCG2). The affinity of kaempferol for ABCG2 was higher than that of quercetin. Therefore, ABCG2 transports kaempferol to the extracellular spaceand leaves quercetin in vivo (175). The second method is to use nanocarriers to increase permeability and achieve systemic circulation by coating nanoparticles on the surface of kaempferol. Nanoparticle capsules may protect kaempferol from efflux transporters and promote the inward transport of cells while maintaining their structural integrity (176). Similarly, nanocurcumin has been used in a number of clinical trails and has achieved certain efficacy.

Kaempferol is a natural product, is a promising antidiabetic drug. This review provides a systematic summary of the pharmacological mechanisms of kaempferol for the treatment of diabetes. This is a systematic summary of animal and cell experiments. Although this review has some limitations, it adds valuable information that is beneficial in determining new drugs for the treatment of diabetes, from animal research to clinical studies. Large-scale, multicenter, and prospective clinical trials will be conducted in the future to obtain more reliable information.
Author contributions

YY and ZC conceived the idea and topic for the opinion. YY, XZ and HX collected the data. YY wrote the manuscript. LD, HG and CX reviewed the manuscript and contributed to the intellectual scientific content of the manuscript with domain-specific expertise. All authors contributed to the article and approved the submitted version.

Funding

This article was funded by the National Natural Science Foundation of China (No. 81774302), the National Natural Science Foundation of China (No. 8197141539), and the Sichuan province of Traditional Chinese medicine academician reserve candidates development project (No. CRS2021067).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes ID, Ohkogoe, et al. IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract (2018) 138:271–81. doi: 10.1016/j.diabres.2018.02.023

2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. (2011). Available at: https://www.cdc.gov/diabetes/basics/index.html

3. Li Y, Zheng D, Shen D, Zhang X, Zhao X, Liao H. Protective effects of two safflower derived compounds, kaempferol and hydroxysafflor yellow a, on hyperglycaemic stress-induced podocyte apoptosis via modulating of macrophage M1/M2 polarization. J Immunol Res (2020) 2020:2462039. doi: 10.1155/2020/2462039

4. Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: National cross sectional study. BMJ (2020) 28(369):m997. doi: 10.1136/bmj.m997

5. Chaudhury A, Duroor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) (2017) 8.6. doi: 10.3389/fendo.2017.00006

6. Maas J. New approaches in research and development of anti-diabetic drugs: an industry perspective. Ther Adv Endocrinol Metab (2012) 3(4):109–12. doi: 10.1177/2042018812457456

7. Levien TL, Baker DE. New drugs in development for the treatment of diabetes. Diabetes Spectrum (2009) 22(2):92–106. doi: 10.2337/despect.22.2.92

8. Covington C, Christopher R, Davenport M, Fleck P, Meeki QA, Wann ER, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. ClinTher (2008) 30(3):499–512. doi: 10.1016/j.clinthera.2008.03.004

9. Boateng GO, Adams EA, Ode Boateng M, Luginaah IN, Taubaszung MM. Obesity and the burden of health risks among the elderly in Ghana: A population study. PLoS One (2017) 12(1):e0186947. doi: 10.1371/journal.pone.0186947

10. Obesity and Overweight. (2021). Available at: http://www.who.int/mediacentre/factsheets/fs631/en/ (Accessed 4 March 2022).

11. Koja I, Chacińska M, Blachnio-Zabiejska A. Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. Nutrients (2020) 12(5):1305. doi: 10.3390/nu12051305

12. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest (1994) 93(2):870–6. doi: 10.1172/JCI17042

13. Kahn SE, Hull RL, Utschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature (2006) 444(7112):840–6. doi: 10.1038/nature05482

14. Polonsky KS, Given RD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest (1988) 81(2):442–8. doi: 10.1172/JCI113339

15. Kahn SE, Pigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. End J Clin Endocrinol (1993) 42(11):1663–72. doi: 10.2337/diab.42.11.1663

16. Kahn SE. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab (2001) 86:4047–58. doi: 10.1210/jcem.86.7.7713

17. Butler AE, Jansson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 52(1):102–10. doi: 10.2337/diabetes.52.1.102

18. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. Nat Prod (2005) 66(7):1022–37. doi: 10.1021/np030096e

19. Chen SR, Chen XP, Lu J, Wang Y, Wang YT. Potent natural products and herbal medicines for treating liver fibrosis. Clin Med (2015) 15:1077. doi: 10.1086/s13020-015-0036-y

20. Kim JY, Cheon YH, Oh HM, Rho MC, Ekhembhaalter M, Kim MS, et al. Olanzapine acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-CalC ATP7a-NFATc1 signaling, and suppresses bone loss in mice. Bone (2014) 60:104–11. doi: 10.1016/j.bone.2013.12.013

21. Zhang Y, Zhen W, Macphillier P, Liu D. Small molecule kaempferol modulates PDX-1 protein expression and subsequently promotes pancreatic β-cell survival and function via CREB. J Nutr Biochem (2013) 24(4):638–46. doi: 10.1016/j.jnutbio.2012.03.008

22. Calderon-Montoto JM, Burgos-Morin E, Pérez-Guerrero C, López-Lázaro M. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem (2011) 11(4):298–344. doi: 10.2174/138955711793503535

23. Crespo I, García-Medivilla MV, Gutiérrez B, Sánchez-Campos S, Tutón MJ, González-Gallego J. A comparison of the effects of kaempferol and quercetin on cytokine-induced pro-inflammatory status of cultured human endothelial cells. Br J Nutr (2008) 100(5):968–76. doi: 10.1017/S0007114508866683

24. Suh KS, Choi EM, Kwon M, Chon S, Oh S, Woo JT, et al. Kaempferol attenuates 2-deoxy-d-ribose-induced oxidative cellular damage in MC3T3-E1 osteoblastic cells. Biol Pharm Bull (2009) 32(4):746–9. doi: 10.1248/bpb.32.746

25. Mylonis I, Lakka A, Tsakalof A, Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochem Physiol Res Commun (2010) 398(1):74–8. doi: 10.1016/j.bpr.2010.06.038

26. Feng Z, Wang C, Yue J, Meng Q, Wu J, Sun H. Kaempferol-induced GPER upregulation attenuates atherosclerosis via the FSHR/akt/Nrf2 pathway. Pharm Biol (2021) 59(1):1166–16. doi: 10.1080/13880209.2021.1961823

27. Alkhalidy H, Moore W, Wang Y, Luo J, McMillan RP, Zhen W, et al. The flavonoid kaempferol ameliorates streptozotocin-induced diabetes by suppressing hepatic glucose production. Molecules (2018) 23(9):2338. doi: 10.3390/molecules23092338
AMPK/mTOR signaling pathway.

J Nutr Biochem

mice.

j.foodchem.2015.05.088

streptozotocin-induced diabetic rats.

kaempferol, a flavonoid compound, on membrane-bound ATPases in HepG2 cells.

Prod

kaempferol-3,7-O-(alpha)-dirhamnoside from bauhinia for improving oxidative stress-induced atherosclerosis.

Free Rad Biol Med (2018) 118:85–97. doi:10.1016/j.freeradbiomed.2018.02.031

Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of glucose oxidation.

PNAS (2010) 107(8):3441–6. doi:10.1073/pnas.0914798107

Varshney R, Varshney R, Mishra R, Gupta S, Sircar D, Roy P. Kaempferol alleviates of kaempferol as a natural plant flavonoids.

Biochem (2009) 57:212–27. doi:10.1016/j.jnutbio.2018.02.017

Montero M, Lobaton CD, Hernandez-Sanmiguel E, Santodomingo J, Vay L, Moreno A, et al. Direct activation of the mitochondrial calcium unporter by natural plant flavonoids.

Biochem (2004) 38(4 Pt 1):19–24. doi:10.1042/BJ20040990

Bormont F, Hermant A, Bennenga R, Chabert C, Jacob G, Santodomingo J, et al. Targeting mitochondrial calcium uptake with the natural flavonol kaempferol, to promote Metabolism/Secretion coupling in pancreatic β-cells.

Nutrients (2020) 12(1):538. doi:10.3390/nut12010058

Zhang Y, Liu D. Flavonol kaempferol improves chronic hyperglycemia-impaired pancreatic beta-cell viability and insulin secretory function.

Eur J Pharmacol (2015) 759(1-3):325–32. doi:10.1016/j.ejphar.2015.08.011

Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

Lancet (1992) 340(8825):925–9. doi:10.1016/0140-6736(92)91305-8

Schuler LO, Bennett PH, Rauvinis E, Kidd JR, Kidd KK, Esparriza J, et al. Effects of traditional and western environments on prevalence of type 2 diabetes in pima indians in Mexico and the U.S. Diabetes Care (2006) 29(5):1866–8. doi:10.2327/dc06-0138

Perry RJ, Campozero JG, Kurarsa R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA Linkages to lipid accumulation in db/db mice.

J Transl Med (2015) 13(2):331–8. doi:10.1186/s13105-015-0659-4

Koobkokkruad T, et al. Flavonoids kaempferide and 4,2'-dihydroxy-4',5'-methylchalcone inhibit micto cholate expansion and induce apoptosis during the early phase of adipogenesis in 3T3-L1 cells. J Integr Med (2019) 17(4):288–95. doi:10.1016/j.jim.2019.04.004

Li X, Kong LX, Li J, He HX, Zhou YD. Kaempferol suppresses lipid accumulation in macrophages through the downregulation of cluster of differentiation 36 and the upregulation of scavenger receptor class b type 1 and ATP-binding cassette transporters A1 and G1. Int J Mol Med (2013) 31(2):331–8. doi:10.3892/ijmm.2012.1204

Kim D, Hwang HY, Ji ES, Kim J, Yoo S, Kwon JH. Activation of mitochondrial TUFM ameliorates metabolic dysregulation through coordinating autophagy induction.

Commun Biol (2021) 4(1). doi:10.1038/s42003-020-01566-0

Ochiai A, Ohtsab M, Sakamoto K. Kaempferol ameliorates symptoms of metabolic syndrome by improving blood lipid profile and glucose tolerance. Biosci Biotechnol Biochem (2021) 85(10):2169–76. doi:10.1039/d0bb01322b

Tie F, Ding J, Hu N, Dong Q, Chen Z, Wang H. Kaempferol and kaempferide attenuate oleic acid-induced lipid accumulation and oxidative stress in HepG2 cells. Int J Mol Sci (2021) 22(16):8847. doi:10.3390/ijms22168847

Tang H, Zeng Q, Tang T, Wei Y, Pu P. Kaempferide improves glycolipid metabolism disorder by activating PPARγ in high-fat-diet-fed mice. Life Sci (2021) 270:119133. doi:10.1016/j.lfs.2021.119133

Li J, He JS, Kang JH, Shin DH, Park HY, Choi MS, et al. Soy leaf extract containing kaempferol glycosides and phosphoribosyltransferase enhances glucose homoeostasis by enhancing pancreatic β-cell function and suppressing hepatic lipid accumulation in db/db mice. J Agric Food Chem (2015) 63(3):7198–210. doi:10.1021/acs.jafc.5b05169

Hoang MH, Jia Y, Mok B, Jun HJ, Kwong HY, Lee SJ. Kaempferol ameliorates symptoms of metabolic syndrome by regulating activities of liver X receptor β. J Nutr Biochem (2015) 26(8):868–75. doi:10.1016/j.jnutbio.2015.03.005

de Sousa E, Zanatta L, Seifriz I, Creczynski-Pasa TB, Pizzolatti MG, Szoparczuk B, et al. Hypoglycemic effect and antioxidant potential of kaempferol 3,7-O-(alpha)-diharmnoside from bahnia forforacea leaves. J Nat Prod (2004) 67(5):829–32. doi:10.1021/np030531u

Al-Naimar KS, Chandranob G, Veeramani C, Alsaf MA. Ameliorative effect of kaempferol, a flavonoid, on oxidative stress in streptozotocin-induced diabetic rats.

Radoj B (2015) 20(5):198. doi:10.1179/1358020514Y.0000000117

Al-Naimar KS, Veeramani C, Alsaf MA, Chandranob G. Influence of kaempferol, a flavonoid compound, on membrane-bound ATPases in streptozotocin-induced diabetic rats.

Cell Biol (2015) 23(3):355–62. doi:10.1377/cbic.2014.082501

Pothakamury U, Zhang G, Liao Y, Gong D. Inhibitory kinetics and mechanism of kaempferol on α-glucosidase. Food Chem (2016) 190:207–15. doi:10.1016/j.foodchem.2015.05.088

Alkhalidy H, Moore W, Wang A, Loo J, McMillan RP, Wang Y, et al. Kaempferol ameliorates hyperglycemia through suppressing hepatic gluconeogenesis and reducing hepatic insulin sensitivity in diet-induced obese mice. J Nutr Biochem (2018) 58:90–101. doi:10.1016/j.jnutbio.2018.04.014

Varshney R, Gupta S, Roy P. Cytotoxic protective effect of kaempferol against palmitic acid-induced pancreatitis-cell death through modulation of autophagy via AMPK/mTOR signaling pathway. Mol Cell Endocrinol (2017) 448:1–20. doi:10.1016/j.mce.2017.02.033
114. Fang XK, Gao J, Zhu DN. Kemptor and quercetin isolated from cyanomusci latius improve glucose uptake of STZ-LI cells without adipecogenesis activity. Life Sci (2008) 82(12-13):615–22. doi: 10.1016/j.lfs.2007.12.021

115. Bhattacharya S, Christensen KR, Olsen LC, Christensen LP, Grevenk K, Faergeman NJ, et al. Bioactive components from flowers of sambucus nigra l. increase glucose uptake in primary porcine myobute cultures and reduce fat accumulation in caonorbubitis elegans. J Agri Food Chem (2013) 61(46):11033–40. doi: 10.1021/jf402838a

116. Matschinsky FM, Magnuzzo MA, Zelent D, Jetten TL, Dolha N, Han Y, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activation for diabetes therapy. Diabetologia (2006) 51(1):1–12. doi: 10.2337/db05-0926

117. Hauser RA, Kastner KH, Accili D. FoxO function synergistically to promote glucose production. J Biol Chem (2010) 285(46):53245–8. doi: 10.1074/jbc.C110.113081

118. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor FoxO1–FoxO3a confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest (2001) 108(9):1359–72. doi: 10.1172/JCI71287

119. Luo C, Yang H, Tang C, Yao G, Kong L, He H, et al. Kemptor alleviates insulin resistance via hepatic Ikk/NF-kB signal in type 2 diabetic rats. Int Immunopharmacol (2015) 28(1):744–50. doi: 10.1016/j.intimp.2015.07.018

120. Hardie DG. AMPK: A key regulator of energy balance in the single cell and the whole organism. Int J Obs (Lond) (2008) 32 Suppl 4:475–12. doi: 10.1038/pnajl.2008.116

121. Steenber GP, Kemp BE. AMPK in health and disease. Physiol Rev (2009) 89(3):985–1028. doi: 10.1152/physrev.00120.2008

122. Rudermer NB, Carling D, Pretmkli M, Caccidol JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest (2013) 123(7):2764–72. doi: 10.1172/JCI62727

123. McGarry JD, Mannapaer GT, Foster DW. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest (1977) 60(1):265–70. doi: 10.1172/JCI70876

124. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2006) 110(2):452–60. doi: 10.1172/JCI259207

125. Oyadomori S, Takeguchi M, Gotoh T, Matsumoto M, Wada I, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activation for diabetes therapy. Diabetologia (2006) 51(1):1–12. doi: 10.2337/db05-0926
159. Falcão-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev (2012) 17(3):325–44. doi:10.1007/s10741-011-9257-z

160. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia (2014) 57(4):660–71. doi:10.1007/s00125-014-3171-6

161. Alshehri AS, El-Kott AF, Eleawa SM, El-Gerbed MSA, Khalifa HS, El-Kenawy AE. Kaempferol protects against streptozotocin-induced diabetic cardiomyopathy in rats by a hypoglycemic effect and upregulating SIRT1. J Physiol Pharmacol (2021) 72(3):339–55. doi:10.26402/jpp.2021.3.04

162. Chen X, Qian J, Wang L, Li J, Zhao Y, Han J. Kaempferol attenuates hyperglycemia-induced cardiac injuries by inhibiting inflammatory responses and oxidative stress. Endocrine (2018) 60(1):83–94. doi:10.1007/s12020-018-1525-4

163. Suchal K, Malik S, Khan SI, Malhotra RK, Goyal SN, Bhatia J, et al. Molecular pathways involved in the amelioration of myocardial injury in diabetic rats by kaempferol. Int J Mol Sci (2017) 18(5):1001. doi:10.3390/ijms18051001

164. Özay Y, Güzel Ş, Yumrutasoğlu B, Pehlivanoglu B, Erdogdu İ, Yildirim Z, et al. Wound healing effect of kaempferol in diabetic and nondiabetic rats. J Surg Res (2019) 233:284–96. doi:10.1016/j.jss.2018.08.009

165. Kishore L, Kaur N, Singh R. Effect of kaempferol isolated from seeds of erucia sativa on changes of pain sensitivity in streptozotocin-induced diabetic neuropathy. Inflammopharmacology (2018) 26(4):993–1003. doi:10.1007/s10787-017-0416-2

166. Oliver FJ, Ménissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J (1999) 18(16):4446–54. doi:10.1093/emboj/18.16.4446

167. Kauppinen TM, Gan L, Swanson RA. Poly(ADP-ribose) polymerase-1-induced NAD(+) depletion promotes nuclear factor-kB transcriptional activity by preventing p65 de-acetylation. Biochim Biophys Acta (2013) 1833(8):1985–91. doi:10.1016/j.bbamcr.2013.04.005

168. Pang J, Cui J, Gong H, Xi C, Zhang TM. Effect of NAD on PARP-mediated insulin sensitivity in oleic acid treated hepatocytes. J Cell Physiol (2015) 230(7):1607–13. doi:10.1002/jcp.24907

169. Pang J, Xi C, Jin J, Han Y, Zhang TM. Relative quantitative comparison between lipotoxicity and glucotoxicity affecting the PARP-NAD-SIRT1 pathway in hepatocytes. Cell Physiol Biochem (2013) 32(3):719–27. doi:10.1159/000354474

170. Heller B, Wang ZQ, Wagner FF, Radons J, Biézle A, Fehe O, et al. Inactivation of the poly(ADP-ribose)-polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J Biol Chem (1995) 270(19):11176–80. doi:10.1074/jbc.270.19.11176

171. Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, et al. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med (1999) 5(3):314–9. doi:10.1038/6535

172. Janssen K, Mensink RP, Cox FJ, Haryyan JL, Hovenier R, Holliman PC, et al. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: Results from an in vitro and a dietary supplement study. Am J Clin Nutr (1998) 67(2):255–62. doi:10.1093/ajcn/67.2.255

173. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Delivery Rev (2003) 55(1):3–29. doi:10.1016/s0169-409x(02)00169-2

174. Gupta A, Kaur CD, Saraf S, Saraf S. Formulation, characterization, and evaluation of ligand-conjugated biodegradable quercetin nanoparticles for active targeting. Artif Cells Nanomed Biotechnol (2016) 44(3):960–70. doi:10.3109/21691401.2015.1008503

175. An G, Gallegos J, Morris ME. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab Dispos (2011) 39(3):426–32. doi:10.1124/dmd.110.035212

176. Luo H, Jiang B, Li B, Li Z, Jiang BH, Chen YC. Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability. Int J Nanomed (2012) 7:3991–9. doi:10.2147/IJN.2012.536670